Search results for "Antibodies."

showing 10 items of 1857 documents

Relapse Rate in Survivors of Acute Autoimmune Thrombotic Thrombocytopenic Purpura Treated with or without Rituximab.

2018

Background Autoimmune thrombotic thrombocytopenic purpura (iTTP) is caused by autoantibody-mediated severe a disintegrin and metalloprotease with thrombospondin type 1 repeats, member 13 (ADAMTS13) deficiency leading to micro-angiopathic haemolytic anaemia (MAHA) and thrombocytopenia with organ damage. Patients survive with plasma exchange (PEX), fresh frozen plasma replacement and corticosteroid treatment. Anti-CD20 monoclonal antibody rituximab is increasingly used in patients resistant to conventional PEX or relapsing after an acute bout. Objective This retrospective observational study focused on the relapse rate and possible influencing factors including treatment with rituximab first…

AdultMalemedicine.medical_specialtyAdolescentautoantibodiesThrombotic thrombocytopenic purpuraADAMTS13 ProteinRelapse rate030204 cardiovascular system & hematologyGastroenterologyAutoimmune Diseases03 medical and health sciencesYoung Adult0302 clinical medicineSex FactorsRecurrenceInternal medicinehemic and lymphatic diseasesCellular Haemostasis and PlateletsMedicineHumansImmunologic Factorsclinical studiesYoung adultChildADAMS/ADAMTS13Retrospective StudiesPurpura Thrombotic Thrombocytopenicbusiness.industryRetrospective cohort studyHematologythrombotic thrombocytopenic purpura (TTP/HUS)Middle Agedmedicine.diseaseAntigens CD20ADAMTS13PurpuraTreatment Outcome030220 oncology & carcinogenesisRituximabFemaleFresh frozen plasmamedicine.symptombusinessRituximabmedicine.drugFollow-Up StudiesThrombosis and haemostasis
researchProduct

Immunoregulatory T-lymphocyte subset deficiency in newly diagnosed Type 1 (insulin-dependent) diabetes mellitus

1984

Humoral and cell-mediated disorders in Type 1 (insulin-dependent) diabetes suggest that an imbalance of immunoregulatory T-cell subsets exists. In 23 newly diagnosed (onset less than 3 months) and 21 long-standing Type 1 diabetic patients, T lymphocyte subsets were analyzed using monoclonal antibodies (OKT3, OKT4, OKT8, OKM1). The newly diagnosed patients showed a reduction with a significant difference from healthy controls in total T cells (OKT3+: 58.1 +/- 8.5% versus 70.7 +/- 8.0%), helper/inducer cells (OKT4+: 33.8 +/- 7.0% versus 47.1 +/- 8.3%), suppressor/cytotoxic cells (OKT8+: 18.5 +/- 7.3% versus 32 +/- 6.8%) and monocytes (OKM1+: 11.5 +/- 3.8% versus 19.9 +/- 5.2%) (p less than 0.…

AdultMalemedicine.medical_specialtyAdolescentmedicine.drug_classT-LymphocytesEndocrinology Diabetes and Metabolismchemical and pharmacologic phenomenaNewly diagnosedBiologyMonoclonal antibodymedicine.disease_causeT-Lymphocytes RegulatoryMonocytesAutoimmunityPathogenesisIslets of LangerhansLeukocyte CountDiabetes mellitusInternal medicineInternal MedicinemedicineHumansCytotoxic T cellChildType 1 diabetesImmunologic Deficiency SyndromesAntibodies MonoclonalT-Lymphocytes Helper-InducerT lymphocytemedicine.diseaseDiabetes Mellitus Type 1EndocrinologyFemaleT-Lymphocytes CytotoxicDiabetologia
researchProduct

The influence of high dose intravenous immunoglobulins on immunological and metabolic pattern in newly diagnosed type I diabetic patients

1990

In autoimmune disease the functional deficiency of T suppressor cells, also described in Type I diabetes, may be restored through immunoglobulin (Ig) infusion, which increases antigen phagocytosis, NK activity, cell clones and antibody anti-idiotype responses. Sixteen Type I diabetic patients were studied: eight were treated soon after the initial correction of disease-onset glycemic deterioration with intensive intravenous (i.v.) 7S Ig treatment (0.4 g/kg/BW) for 1 week and once per week for 6 months, whilst the remaining patients constituted the control group. All patients were evaluated during the study for metabolic and immunological parameters. A reduction in insulin requirement compar…

AdultMalemedicine.medical_specialtyAdolescentmedicine.medical_treatmentPhagocytosisImmunologyCellAutoimmune DiseasesRandom AllocationAntigenInternal medicinemedicineHumansInsulinImmunology and AllergyChildAutoantibodiesGlycemicAutoimmune diseaseC-Peptidebiologybusiness.industryInsulinImmunization PassiveReceptors Interleukin-2medicine.diseaseDiabetes Mellitus Type 1medicine.anatomical_structureEndocrinologyIntravenous ImmunoglobulinsChild Preschoolbiology.proteinFemaleAntibodybusinessJournal of Autoimmunity
researchProduct

Two-year effectiveness and safety of golimumab in ulcerative colitis: An IG-IBD study

2020

Abstract Background Few data exist regarding the long‐term effectiveness of golimumab in ulcerative colitis. No data have been reported on real‐world continuous clinical response. Objective This study aimed to describe the long‐term outcomes in a large cohort of patients on golimumab who had ulcerative colitis. Methods Consecutive patients with active ulcerative colitis, started on golimumab, were enrolled and prospectively followed up. The primary end point was to evaluate the long‐term persistence on golimumab therapy. Results A total of 173 patients with ulcerative colitis were studied. Of these, 79.2% were steroid dependent, and 46.3% were naïve to anti‐tumour necrosis factor alpha agen…

AdultMalemedicine.medical_specialtyAdolescentnaïveGolimumabPersistence (computer science)03 medical and health sciencesYoung Adult0302 clinical medicineremissionGastrointestinal AgentsInternal medicinemedicineHumansProspective StudiesAgedRetrospective Studiesulcerative colitisbusiness.industryTumor Necrosis Factor-alphaInflammatory Bowel DiseaseGastroenterologyAntibodies MonoclonalpersistenceMiddle Agedmedicine.diseaseUlcerative colitisGolimumabGolimumab; naïve; persistence; remission; ulcerative colitisOncology030220 oncology & carcinogenesis030211 gastroenterology & hepatologyColitis UlcerativeFemaleOriginal Articlebusinessmedicine.drugFollow-Up StudiesIBD Ulcerative colitis Golimumab TNF-inhibitors
researchProduct

Treatment of relapsing-remitting multiple sclerosis after 24 doses of natalizumab: evidence from an Italian spontaneous, prospective, and observation…

2014

Importance The evaluation of therapeutic choices is needed after 24 doses of natalizumab in patients with multiple sclerosis (MS). Objective To evaluate the effect of therapeutic choices on the mean annualized relapse rate and on magnetic resonance imaging MS activity after 24 doses of natalizumab in patients with relapsing-remitting MS. Design, Setting, and Participants The TY-STOP study, which recruited participants between October 22, 2010, and October 22, 2012, at 8 Italian MS centers (secondary care outpatient clinics) among 124 adult patients who demonstrated no clinical or magnetic resonance imaging MS activity after 24 doses of natalizumab. Interventions Natalizumab, no treatment, i…

AdultMalemedicine.medical_specialtyAdult; Antibodies Monoclonal Humanized; Humans; Italy; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Sclerosis Relapsing-Remitting; Natalizumab; Prospective Studies; Recurrence; Treatment OutcomeAntibodies Monoclonal HumanizedNatalizumabMultiple Sclerosis Relapsing-RemittingRecurrenceInternal medicineClinical endpointmedicineOutpatient clinicHumansProspective StudiesGlatiramer acetateMultiple Sclerosis Ty-STOP Natalizumabbusiness.industryProgressive multifocal leukoencephalopathyNatalizumabMiddle Agedmedicine.diseaseFingolimodMagnetic Resonance ImagingSurgeryDiscontinuationClinical trialTreatment OutcomeItalySettore MED/26 - NeurologiaNeurology (clinical)businessmedicine.drugJAMA neurology
researchProduct

Adalimumab for treatment of moderate to severe psoriasis and psoriatic arthritis

2008

Psoriasis and psoriatic arthritis are common diseases associated with considerable morbidity and disability. Their pathophysiology comprises similar processes leading to inflammation of skin, entheses, and joints. Although traditional systemic agents can be effective, their use may be limited by lack of efficacy and concerns regarding adverse effects. The objective of this study was to assess the efficacy and safety of adalimumab, a fully human antitumor necrosis factor (anti-TNF) monoclonal antibody, over 16 weeks. The present authors report their personal experience in 15 patients with severe plaque psoriasis and psoriatic arthritis, refractory to other treatments, in which a decisive reg…

AdultMalemedicine.medical_specialtyAnti-Inflammatory AgentsArthritisDermatologyAntibodies Monoclonal HumanizedSeverity of Illness IndexPsoriasis Psoriatic ArthritisPsoriatic arthritisPsoriasisSeverity of illnessSettore MED/35 - Malattie Cutanee E VenereemedicineAdalimumabHumansPsoriasisAdverse effectTumor Necrosis Factor-alphabusiness.industryArthritis PsoriaticAdalimumabAntibodies MonoclonalGeneral MedicineMiddle Agedmedicine.diseaseDermatologyRadiographyClinical trialTreatment OutcomeMonoclonalFemalebusinessmedicine.drugDermatologic Therapy
researchProduct

Does an 'autoimmune' profile affect the clinical profile of chronic hepatitis C? An Italian multicentre survey.

2004

SUMMARY. Nonorgan-specific autoantibodies (NOSA) are common in patients with chronic hepatitis C virus infection. It is unclear whether serological markers of autoimmunity segregate in a cohort of cases with more severe liver damage. We assessed the relationship between NOSA and demographic, biochemical and histological features in 502 subjects with anti-HCV positive, HCV-RNA positive, HBsAg negative chronic hepatitis consecutively referred to four Italian liver units. Percutaneous liver biopsy was performed in all subjects. A single pathologist scored the biopsies using histology activity index classification. The overall prevalence of positivity for any NOSA was 36.9%. Antinuclear antibod…

AdultMalemedicine.medical_specialtyAnti-nuclear antibodyAdolescentAutoimmunityInterferon alpha-2medicine.disease_causeGastroenterologyAntiviral AgentsAutoimmunitySerologyLiver diseaseVirologyInternal medicinemedicineHumansAdverse effectAgedAutoantibodiesHepatologybiologybusiness.industryAutoantibodyInterferon-alphaHepatitis C ChronicMiddle Agedmedicine.diseaseRecombinant ProteinsInfectious DiseasesItalyAntibodies AntinuclearImmunologyCohortbiology.proteinDrug Therapy CombinationFemaleAntibodybusinessJournal of viral hepatitis
researchProduct

Binding of monocytes from normolipidemic hyperglycemic patients with type 1 diabetes to endothelial cells is increased in vitro.

2009

Increased endothelial binding and emigration of monocytes play a dominant role in the pathogenesis of atherosclerosis in diabetes mellitus. Previous studies revealed that hyperlipidemia correlates with monocyte binding in vitro. The aim of this study was to characterize the monocyte-endothelial interaction of leucocytes of hyperglycemic patients with type 1 diabetes but lacking hyperlipidemia. We isolated monocytes from healthy controls and normolipidemic type 1 diabetes patients with elevated levels of HbA1c and quantified monocyte binding by an immunoilluminometric cell adhesion assay. Purity of isolated monocytes was at least 98%. Endothelial binding of monocytes from patients with type …

AdultMalemedicine.medical_specialtyArteriosclerosisEndocrinology Diabetes and MetabolismCell CountMonocytesPathogenesischemistry.chemical_compoundEndocrinologyInternal medicineDiabetes mellitusHyperlipidemiaInternal MedicinemedicineCell AdhesionHumansType 1 diabetesbusiness.industryCD11 AntigensImmunomagnetic SeparationMonocyteAntibodies MonoclonalGeneral Medicinemedicine.diseaseFlow CytometryIn vitroEndothelial stem cellEndocrinologymedicine.anatomical_structureDiabetes Mellitus Type 1GlucoseL-GlucosechemistryHyperglycemiaLuminescent MeasurementsMultivariate AnalysisRegression AnalysisFemaleEndothelium VascularbusinessExperimental and clinical endocrinologydiabetes : official journal, German Society of Endocrinology [and] German Diabetes Association
researchProduct

Exposure to HAV infection in patients with chronic liver disease in Italy, a multicentre study*.

2005

Summary.  We carried out a multicentre study on 2830 patients with chronic liver disease from 79 liver units (25 in northern, 24 in central and 30 in southern Italy) to evaluate naturally acquired immunity against hepatitis A virus (HAV) in relation to age, sex, geographical area of origin and entity of liver disease, and to define the strategy for specific vaccination. Antibody to HAV (anti-HAV) was detected in 1514 (53.5%) of the 2830 patients tested; the prevalence was 50.4% in males and 59.1% in females. Both in central and southern Italy the prevalence of anti-HAV positive subjects increased with increasing age from 43.3 and 44.7%, respectively, in the 0–30-year-old subjects to 80.1 an…

AdultMalemedicine.medical_specialtyCirrhosisAdolescentHepatitis A AntibodiesChronic liver diseaseLiver diseaseSeroepidemiologic StudiesVirologyInternal medicinePrevalencemedicineHumansIn patientChildChronic liver disease HAV infection HAV vaccination HBV chronic infection HCV chronic infection Total anti-HAVAgedAged 80 and overHigh prevalenceHepatologybiologybusiness.industryLiver DiseasesInfantHepatitis AHepatitis AMiddle Agedmedicine.diseaseVaccinationCross-Sectional StudiesInfectious DiseasesItalyChild PreschoolImmunoglobulin GChronic DiseaseImmunologybiology.proteinFemaleAntibodybusinessHepatitis A Virus Human
researchProduct

Transfusion-associated chronic hepatitis C: alpha-n1 interferon for 6 vs. 12 months.

1996

Abstract Aims: To compare the long-term effects of brief and prolonged therapy with alpha-n 1 interferon for transfusion-associated chronic hepatitis C. Methods: One hundred and sixteen subjects (male/female 4868, mean age 46.9 years) were studied. Sixty patients were randomised to brief treatment (group 1: interferon 5 Mu/msq. t.i.w. for 2 months, then 3 Mu/msq. t.i.w. for 4 months), and 56 to prolonged treatment (group 2: interferon 5 Mu/msq. t.i.w. for 2 months, then 3 Mu/msq. t.i.w. for 10 months). All were followed for 12 months after stopping interferon. Results: The early response rate was 47.4% (Group 1 [45%], Group 2 [50%]). No "breakthrough" reactivations were observed. The early …

AdultMalemedicine.medical_specialtyCirrhosisAdolescentmedicine.medical_treatmentHepatitis C virusPopulationAlpha interferonmedicine.disease_causeGastroenterologyAntibodiesDrug Administration ScheduleInterferonInternal medicinemedicineHumanseducationInterferon alfaAgededucation.field_of_studyHepatologybusiness.industryInterferon-alphaTransfusion ReactionImmunotherapyMiddle Agedmedicine.diseaseHepatitis CSurgeryChronic DiseaseFemalebusinessComplicationmedicine.drugJournal of hepatology
researchProduct